Renovaro announced that it will change its corporate name to “Lunai Bioworks” to better reflect its strategic direction and growing expertise in AI-powered biodefense, drug discovery and advanced diagnostics. The new name underscores the company’s commitment to harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. The name change was approved by the Board of Directors, and the company’s common stock will continue to trade on Nasdaq under its current ticker symbol, RENB, until further notice.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RENB:
- Renovaro Biosciences Granted Nasdaq Compliance Extension
- Renovaro BioSciences secures multiple U.S. patents in biomedical AI
- Renovaro Biosciences Chairman Announces Resignation
- Renovaro BioSciences announces publication of study on dendritic cell therapy
- Renovaro Biosciences Receives Nasdaq Compliance Notice